Reprogramming the allergic immune response through subcutaneous or sublingual allergen dose escalation
Allergen immunotherapy (AIT) is the only disease-modifying treatment for IgE-mediated allergic rhinitis, allergic asthma, and stinging-insect hypersensitivity. Treatment begins with a highly dilute standardized allergen extract, dosed subcutaneously (SCIT) or sublingually (SLIT), at a level far below any dose expected to trigger a systemic reaction — establishing the safety margin from which escalation proceeds.
Modern therapeutic allergen extracts are standardized against a reference preparation using major allergen content (µg/mL of the dominant IgE-binding protein, e.g., Der p 1 for house dust mite, Amb a 1 for ragweed) or bioequivalent allergy units (BAU/mL), replacing older, inconsistent "protein nitrogen unit" (PNU) systems. Standardization allows reproducible dosing across lots and manufacturers.
Starting dose selection is guided by skin-prick or intradermal test titration: the more reactive the patient's skin test endpoint, the more dilute the starting concentration. A typical SCIT build-up begins at 1:1,000,000 to 1:100,000 w/v dilution of the maintenance concentrate (roughly 0.1–1 ng of major allergen protein per injection) — thousands of times below the eventual maintenance dose.
Sublingual immunotherapy (SLIT), delivered as drops or a fast-dissolving tablet held under the tongue, generally starts closer to (or occasionally at) the maintenance dose because the oral mucosal route and first-dose in-office observation confer a substantially lower systemic reaction risk than injections.
Three build-up strategies trade speed for monitoring intensity:
• Conventional: one injection per week, dose increased in small increments (~10–20% per visit) across 20–28 visits — reaching maintenance in roughly 3–6 months. Lowest reaction risk; the historical default.
• Cluster: two to three incremental injections given per visit, 30 minutes apart, on non-consecutive treatment days — compressing build-up to 4–8 weeks. Modestly higher systemic reaction rate than conventional dosing, offset by closer in-visit observation.
• Rush: multiple escalating injections given every 15–60 minutes over one to several days in a monitored clinic or infusion-unit setting, reaching maintenance within days. Highest systemic reaction risk of the three; typically reserved for venom immunotherapy or time-sensitive cases, and often paired with premedication.
Each build-up visit increases the allergen dose by a defined increment, guided by the patient's tolerance at the prior visit. Because the systemic reaction risk is concentrated in this escalation window, every subcutaneous dose increase is followed by a structured observation period and explicit rules for holding or reducing the dose.
At each visit, the dose is advanced along a pre-printed build-up schedule as long as the previous injection was tolerated without a large local reaction (wheal/erythema >5 cm at 20–30 minutes) or any systemic symptoms. If a large local reaction occurs, the dose is typically repeated or reduced rather than advanced. After a systemic reaction, the protocol requires a substantial dose reduction (commonly 50–75%) and a slower re-escalation, or discontinuation depending on severity.
Other modifiers that trigger dose holds: a missed-dose interval beyond the schedule's tolerance window (doses require reduction if delayed, since accumulated partial tolerance can wane), concurrent uncontrolled asthma, active infection, or recent vaccination — all of which lower the threshold for a systemic reaction.
World Allergy Organization (WAO) grading stratifies systemic reactions from Grade 1 (mild cutaneous symptoms only) through Grade 5 (fatal anaphylaxis), guiding both immediate management and subsequent dose adjustment. The overwhelming majority of systemic reactions to SCIT begin within 30 minutes of injection, which is why guidelines mandate in-clinic observation for at least that period (up to 60 minutes for patients with prior systemic reactions or venom immunotherapy) before the patient leaves.
Every injection site must have immediate access to injectable epinephrine, antihistamines, and resuscitation equipment. Biphasic reactions — recurrence of anaphylaxis symptoms hours after apparent resolution — occur in under 1% of systemic reactions but are the rationale for extended monitoring in high-risk patients.
US allergy-practice surveillance (Bernstein et al., and subsequent AAAAI/ACAAI registries) places the fatal systemic reaction rate for SCIT at roughly 1 per 2.5 million injections — comparable in order of magnitude to other elective medical injections — underscoring why observation protocols and epinephrine availability remain non-negotiable.
The central immunologic event of allergen immunotherapy is not simply "more allergen exposure" but a qualitative reprogramming of the adaptive immune response. Repeated, escalating allergen doses presented by dendritic cells in a tolerogenic context drive the expansion of allergen-specific regulatory T cells (Tregs), progressively dampening the Th2-skewed response that drives allergic symptoms.
High, repeated allergen doses are captured by tissue dendritic cells at the injection or mucosal site and presented to naive and memory CD4+ T cells in regional lymph nodes. Unlike the low-dose, adjuvant-rich exposure that favors Th2 priming in natural allergic sensitization, the immunotherapy dosing context — combined with locally elevated IL-10 and TGF-β — favors differentiation of allergen-specific CD4+CD25+Foxp3+ Tregs and type 1 regulatory (Tr1) cells instead of further Th2 expansion.
These induced Tregs are allergen-specific: they recognize the same peptide-MHC complexes as the pathogenic Th2 cells they suppress, allowing targeted, rather than global, immunosuppression. Detectable increases in allergen-specific Treg frequency and function are typically measurable within 4–12 weeks of build-up, well before clinical symptom improvement becomes evident.
Induced Tregs suppress the allergic cascade through several convergent mechanisms:
• IL-10: inhibits Th2 cytokine production (IL-4, IL-5, IL-13), suppresses mast cell and eosinophil activation, and drives B cells toward IgG4 rather than IgE class switching.
• TGF-β: promotes additional peripheral Treg induction (a self-amplifying loop) and contributes to IgA class switching at mucosal surfaces.
• T-cell anergy: high-dose allergen exposure can render allergen-specific effector T cells hyporesponsive independent of Treg suppression, particularly early and at very high cumulative doses.
• Cytokine milieu shift: as Treg and regulatory cytokine output rises, the local and systemic balance moves away from a Th2-dominant profile toward one with relatively greater Th1 (IFN-γ) and regulatory tone — reducing eosinophil recruitment, mast cell priming, and IgE-driven mucosal inflammation.
The magnitude of allergen-specific Treg induction during the first months of immunotherapy has been correlated with eventual clinical response, making it one of the leading candidate biomarkers for predicting which patients will benefit most from a multi-year course.
In parallel with T-cell reprogramming, allergen immunotherapy drives a humoral shift: allergen-specific IgG4 antibodies rise sharply, often 10- to 100-fold above baseline over the first year. These "blocking antibodies" intercept allergen before it can cross-link IgE on mast cells and basophils, providing a second, independent layer of tolerance.
IgG4, normally a minor serum immunoglobulin subclass, becomes the dominant allergen-specific antibody isotype induced by immunotherapy. IL-10 from allergen-specific Tregs and Tr1 cells drives B cells toward IgG4 (and, at mucosal sites, IgA) class switching rather than IgE. Functionally, IgG4 binds allergen with high avidity but — because it engages only low-affinity, largely inhibitory Fc receptors and does not efficiently cross-link FcεRI on mast cells and basophils — it does not itself trigger degranulation.
By competing directly with cell-bound IgE for the same allergen epitopes, allergen-specific IgG4 functions as a molecular decoy: it captures allergen in solution before it can bridge adjacent IgE molecules on the mast cell surface, blunting the degranulation signal even while measurable IgE remains present. The facilitated allergen-binding (FAB) assay, which measures the ability of a patient's serum to inhibit IgE-facilitated allergen binding to B cells, is used experimentally to quantify this blocking capacity.
Serum allergen-specific IgE frequently shows a distinctive biphasic pattern during immunotherapy: a transient early rise over the first weeks to months of build-up (reflecting ongoing allergen-driven B-cell activation before regulatory mechanisms dominate), followed by a slow, progressive decline over the following months to years — often eventually falling below pre-treatment baseline after several years of maintenance therapy.
Clinically, this means IgE levels are a poor early marker of treatment success and can be misleading if checked only in the first weeks. The IgE/IgG4 ratio, tracked longitudinally, correlates better with symptom improvement than either antibody alone, since it captures both the loss of pro-allergic signaling capacity and the gain of competing blocking antibody.
Because functional blocking capacity depends on the relative abundance and avidity of IgG4 versus IgE — not on IgG4 concentration in isolation — some patients achieve strong clinical tolerance despite only modest absolute IgG4 rises, while others with large IgG4 increases respond more slowly; Treg-driven qualitative changes in antibody affinity likely explain part of this gap.
Once the maintenance dose is reached, the treatment goal shifts from escalation to consolidation: regular dosing over three to five years reinforces the regulatory T-cell and IgG4-dominant antibody response established during build-up, driving measurable and durable reductions in symptoms and rescue medication use — with benefit that can persist for years after treatment stops.
Once the target maintenance dose is reached — typically corresponding to 5–20 µg of major allergen protein per SCIT injection, or the labeled maintenance concentration for SLIT tablets/drops — injection frequency is spaced out, commonly to every 4 weeks initially and eventually every 6–8 weeks, while daily dosing continues uninterrupted for SLIT. This maintenance interval is long enough to avoid excessive injection burden but short enough to sustain the regulatory T-cell and IgG4 responses established during build-up; intervals stretched too far risk partial waning of tolerance and can require a dose reduction on resumption.
Multi-year duration is essential: shorter courses (under 3 years) show attenuated long-term benefit after stopping compared with the 3–5 year courses used in pivotal trials. The World Allergy Organization and major national guidelines converge on 3 years as a practical minimum for durable, disease-modifying effect.
Efficacy is tracked using combined symptom-medication scores (daily patient-reported nasal/ocular/asthma symptom severity plus rescue antihistamine or bronchodilator use), visual analog scales, and standardized quality-of-life questionnaires. Meta-analyses across allergic rhinitis and asthma immunotherapy trials consistently show combined symptom-medication score reductions on the order of 30–40% relative to placebo by the second maintenance year, with continued modest improvement thereafter.
Because both Treg induction and the IgG4/IgE shift progress gradually, clinical benefit typically becomes noticeable only after several months of build-up and continues to deepen throughout the maintenance years — a key point for setting patient expectations at treatment initiation.
The defining advantage of immunotherapy over symptomatic pharmacotherapy is that its benefit persists after treatment stops. Landmark long-term follow-up studies of grass-pollen SCIT and SLIT (including work from the Durham group) have demonstrated maintained symptom reduction and reduced medication use for 7–12 years after a 3-year course was completed, consistent with durable immunologic memory in the Treg and IgG4-producing B-cell compartments rather than a purely transient desensitization effect.
Not all patients achieve this durable, disease-modifying outcome — courses shorter than 3 years, poor adherence (particularly relevant for daily SLIT dosing), and discontinuation before maintenance is reached are all associated with more rapid loss of benefit after stopping.
Long-term remission after a completed 3–5 year immunotherapy course is the clearest evidence that AIT is disease-modifying rather than merely symptom-suppressive — a distinction no antihistamine, intranasal steroid, or biologic currently on the market can claim.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Route | Subcutaneous injection (SCIT) | Clinic-administered injection into upper arm subcutaneous tissue | Decades of efficacy data; broadest allergen/multi-allergen use |
| Route | Sublingual tablet/drops (SLIT) | Self-administered daily dose held under the tongue | No needles; first dose only requires in-office observation |
| Schedule | SCIT: weekly build-up → monthly maintenance | 20–28 build-up visits (conventional) then 4–8 wk maintenance intervals | Flexible dose titration at each visit |
| Schedule | SLIT: daily dosing, near-maintenance start | Continuous daily home dosing, minimal build-up phase | Lower visit burden; better suited to home use |
| Systemic reaction risk | SCIT: ~0.1–0.2% of injections | Fatal reaction ~1 per 2.5M injections (US surveillance) | Well-characterized safety monitoring protocols |
| Systemic reaction risk | SLIT: lower than SCIT | Local oral/GI reactions common; severe systemic reactions rare | No epinephrine auto-injector mandated in most guidelines |
| Efficacy evidence | SCIT: strong, multi-decade RCT base | Robust data across rhinitis, asthma, and venom allergy | Preferred for multi-allergen sensitization, venom allergy |
| Efficacy evidence | SLIT: strong for single major allergens | Grass, ragweed, HDM tablets FDA/EMA-approved with RCT support | Comparable durable benefit for approved single-allergen products |